CAS: 851528-79-5; Seladelpar

该化合物是一种合成有机化合物,其结构复杂,包括多种功能组,如乙酸藻,乙氧组和三氟甲基代苯环.该化合物一般被归类为硫醚,因为其结构中存在硫磺原子,有助于其独特的化学特性.它表现出高脂性,有可能用于制药应用,特别是在药物设计和开发中.三氟甲基组增强了其生物活动和稳定性,而乙氧和苯氧组可能会影响其溶性以及与生物目标的相互作用.

结构式图片

上下游产品

(R)-{4-[2-Ethoxy-3-(4-Trifluoromethyl-Phenoxy)-Propylsulfanyl]-2-Methyl-Phenoxy}-Acetic Acid Ethyl Ester 851528-83-1
(R)-{4-[2-Hydroxy-3-(4-Trifluoromethyl-Phenoxy)-Propylsulfanyl]-2-Methyl-Phenoxy}-Acetic Acid Ethyl Ester 851528-81-9
Ethyl [(4-Mercapto-2-Methylphenyl)Oxy]Acetate 343322-82-7

合成工艺路线路线简述

    📜对三氟甲基苯酚置于lithium Hydroxide,四丁基氟化铵,Sodium Hydride体系中,用 四氢呋喃 作为反应溶剂,化学反应生成 司拉德帕
    参考文献:Discovery Of Para-Alkylthiophenoxyacetic Acids As A Novel Series Of Potent And Selective Pparδ Agonists
    标题:Discovery Of Para-Alkylthiophenoxyacetic Acids As A Novel Series Of Potent And Selective Pparδ Agonists
    摘要:A Novel Series Of Potent And Selective Ppar Delta Agonists,Para-Alkylthiophenoxyacetic Acids,Was Identified. The Synthesis And Structure-Activity Relationships Are Described. (C) 2007 Elsevier Ltd. All Rights Reserved.
    DOI:10.1016/j.Bmcl.2007.05.007

    海关参考信息

    专利信息


    专利号:US-11912647-B2
    优先权日:2020-05-22
    标 题:Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation
    发明人:CRICH DAVID; HETTIKANKANAMALAGE ASIRI; HILL JARVIS
    权利人:UNIV GEORGIA
    摘要:In one aspect, the disclosure relates to a method for the direct synthesis of complex N,N,O-trisubstituted hydroxylamines by N—O bond formation. In another aspect, the method can successfully be employed using a wide variety of commercially available alcohols and secondary amines and enables the construction of large fragment-based libraries of trisubstituted hydroxylamines for drug discovery purposes. Also disclosed are N,N,O-trisubstituted hydroxylamines having low basicity, high stability at ambient temperatures, and an inherent lack of reactivity towards acetylating and sulfonylating enzymes that confer mutagenicity on less-substituted hydroxylamines.

    专利号:US-9908846-B2
    优先权日:2014-02-21
    标题:Composition, synthesis, and use of new arylsulfonyl isonitriles
    发明人:FLEMING FRASER FERGUSSON; LUJAN MONTELONGO JESUS ARMANDO
    权利人:DUQUESNE UNIV OF THE HOLY GHOST; UNIV HOLY GHOST DUQUESNE
    摘要:This invention relates to novel isonitriles, including arylsulfonyl isonitriles, and methods for their synthesis. The isonitriles include a conjugated ring system. The structure is designed with the flexibility to have multiple substitution patterns. The isonitriles may be used in applications including, but not limited to, pharmaceutical compositions.

    专利号:US-2015139987-A1
    优先权日:2013-11-20
    标 题 :Treatment of homozygous familial hypercholesterolemia
    发明人:MARTIN ROBERT L; MCWHERTER CHARLES A; O'MARA PATRICK J
    权利人:CYMABAY THERAPEUTICS INC
    摘要:Treatment of homozygous familial hypercholesterolemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an MTP inhibitor, an apoB-100 synthesis inhibitor, or a PCSK9 inhibitor.

    专利号:US-12358903-B2
    优先权日:2016-06-13
    标题 :FXR (NR1H4) modulating compounds
    发明人:BLOMGREN PETER A; CURRIE KEVIN S; FARAND JULIE; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
    权利人:GILEAD SCIENCES INC
    摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

    专利号:US-11739065-B2
    优先权日:2016-06-13
    标题 :FXR (NR1H4) modulating compounds
    发明人:BLOMGREN PETER A; CURRIE KEVIN S; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
    权利人:GILEAD SCIENCES INC
    摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

    专利号:CN-106045991-A
    优先权日:2016-05-30
    标题 :Application of chlorophyll as a photosensitizer in the synthesis of tetrahydroquinoline derivatives by visible light-catalyzed cyclization reaction

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Vuppalanchi R, Kowdley KV. Editorial: The evolving paradigms and treatments for primary biliary cholangitis. Aliment Pharmacol Ther. 2024 Jan;59(2):280-281. doi: 10.1111/apt.17779. 59(2):186-200. doi: 10.1111/apt.17755. Epub 2023 Oct 30. 59(2):201-216. doi: 10.1111/apt.17762. Epub 2023 Oct 25. 12(8):1523. doi: 10.3390/antiox12081523.
    7: Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6.
    8: Levy C, Manns M, Hirschfield G. New Treatment Paradigms in Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2076-2087. doi: 10.1016/j.cgh.2023.02.005. Epub 2023 Feb 19.

    合成参考文献


    参考文献:10.1210/jc.2011-1061
    摘要:Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, Choi Y, Wang X, Naim S, Roberts BK. MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin. The Journal of Clinical Endocrinology & Metabolism. 2011 Sep;96(9):2889–97. doi: 10.1210/jc.2011-1061.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知